Stock ATOSSA GENETICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Analyst Reco. Atossa Genetics Inc Nasdaq

Equities

US04962H1005

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Atossa Genetics Inc
Apr. 29 Atossa Therapeutics, Inc. Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates and (Z)-Endoxifen CI
Apr. 15 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Atossa Therapeutics Rises After HC Wainwright Starts Coverage with Buy Rating
MT
HC Wainwright Initiates Atossa Therapeutics With Buy Rating, Price Target is $4
MT
Cantor Fitzgerald Starts Atossa Therapeutics at Overweight With $5 Price Target
MT
Maxim Group Adjusts Atossa Therapeutics Price Target to $4 From $7, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATOS Stock
  4. Stock
  5. News Atossa Genetics Inc
  6. Analyst Reco.